Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients with Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)

Circulation

Volumn 136, Issue 25, 2017, Pages 2440-2450

  Bohula, Erin A ^a   Wiviott, Stephen D ^a   Giugliano, Robert P ^a   Blazing, Michael A ^b   Park, Jeong Gun ^a   Murphy, Sabina A ^a   White, Jennifer A ^b   Mach, Francois ^c   Van De Werf, Frans ^d   Dalby, Anthony J ^e   White, Harvey D ^f   Tershakovec, Andrew M ^g   Cannon, Christopher P ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e MILPARK HOSPITAL   (South Africa)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

acute coronary syndrome; ezetimibe; low density lipoprotein cholesterol; risk stratification; secondary prevention; simvastatin; stroke

Indexed keywords

EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; BLOOD; COMPLICATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PLACEBO EFFECT; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ANTICHOLESTEREMIC AGENTS; ATRIAL FIBRILLATION; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLACEBO EFFECT; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; SIMVASTATIN; STROKE; TREATMENT OUTCOME;

EID: 85038413647     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.029095     Document Type: Article

References (23)

1. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liau CS, Mas JL, Röther J, Smith SC Jr, Salette G, Contant CF, Massaro JM, Steg PG, REACH Registry Investigators Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010 304 1350 1357. doi: 10.1001/jama.2010.1322.
2. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Yawn BP, Roger VL, A community-based study of stroke incidence after myocardial infarction. Ann Intern Med 2005 143 785 792
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, Heart disease and stroke statistics: 2016 update: A report from the American Heart Association. Circulation 2016 133 e38 e360. doi: 10.1161/CIR.0000000000000350.
4. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 376 1670 1681
5. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015 372 2387 2397. doi: 10.1056/NEJMoa1410489.
6. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, Tershakovec AM, Braunwald E, Reduction in total cardiovascular events with ezetimibe/simvastatin post-Acute coronary syndrome: The IMPROVE-IT trial. J Am Coll Cardiol 2016 67 353 361. doi: 10.1016/j.jacc.2015.10.077.
7. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM, IMPROVE-IT Investigators Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008 156 826 832. doi: 10.1016/j.ahj.2008.07.023.
8. Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, Reist C, McCagg A, Braunwald E, Califf RM, Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014 168 205.e1 212.e1. doi: 10.1016/j.ahj.2014.05.004.
9. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS, Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-Analysis. JAMA 2016 316 1289 1297. doi: 10.1001/jama.2016.13985.
10. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017 376 1713 1722. doi: 10.1056/NEJMoa1615664.
11. Ariesen MJ, Claus SP, Rinkel GJ, Algra A, Risk factors for intracerebral hemorrhage in the general population: A systematic review. Stroke 2003 34 2060 2065. doi: 10.1161/01.STR.0000080678.09344.8D.
12. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 355 549 559. doi: 10.1056/NEJMoa061894.
13. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, Zivin JA, Welch KM, SPARCL Investigators Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008 70 24 Pt 2 2364 2370. doi: 10.1212/01.wnl.0000296277.63350.77.
14. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, MacMahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdel BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y, Mrkobrada M, Statins and intracerebral hemorrhage: collaborative systematic review and meta-Analysis. Circulation 2011 124 2233 2242. doi: 10.1161/CIRCULATIONAHA.111.055269.
15. Westover MB, Bianchi MT, Eckman MH, Greenberg SM, Statin use following intracerebral hemorrhage: A decision analysis. Arch Neurol 2011 68 573 579. doi: 10.1001/archneurol.2010.356.
16. Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E, Long-Term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: A prespecified analysis of the IMPROVE-IT Trial. JAMA Cardiol 2017 2 547 555. doi: 10.1001/jamacardio.2017.0083.
17. Blazing MA, Giugliano RP, de Lemos JA, Cannon CP, Tonkin A, Ballantyne CM, Lewis BS, Musliner TA, Tershakovec AM, Lokhnygina Y, White JA, Reist C, McCagg A, Braunwald E, On-Treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J 2016 182 89 96. doi: 10.1016/j.ahj.2016.09.004.
18. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG, Effect of alirocumab, a monoclonal antibody to PCSK9, on long-Term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 2014 168 682 689. doi: 10.1016/j.ahj.2014.07.028.
19. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC, SPIRE Cardiovascular Outcome Investigators Cardiovascular efficacy and safety of Bococizumab in high-risk patients. N Engl J Med 2017 376 1527 1539. doi: 10.1056/NEJMoa1701488.
20. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010 137 263 272. doi: 10.1378/chest.09-1584.
21. Friberg L, Rosenqvist M, Lip GY, Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J 2012 33 1500 1510. doi: 10.1093/eurheartj/ehr488.
22. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R, LAPLACE-2 Investigators Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial. JAMA 2014 311 1870 1882. doi: 10.1001/jama.2014.4030.
23. Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM, Lipid-Altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012 223 251 261. doi: 10.1016/j.atherosclerosis.2012.02.016.